Immune Checkpoint Inhibitors in RCC

At the conclusion of this activity, participants will be able to:

1. Discuss the current immunotherapy options available for the treatment of RCC.

2. Describe both completed and accruing clinical trials that are defining the paradigms of immunotherapy use in RCC.

3. Identify and manage immune related adverse events.

This educational series is supported by independent educational grants from:

Astellas

AstraZeneca

Bristol Myers Squibb

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Merck

Pfizer, Inc

Sanofi Genzyme

UroGen Pharma, Inc.

CME Available: https://auau.auanet.org/node/29846